Cytokinetics, Inc., South San Francisco, CA, USA.
Alzheimers Dement. 2013 Feb;9(1 Suppl):S45-55. doi: 10.1016/j.jalz.2011.11.002. Epub 2012 Jun 1.
We used the database of the Alzheimer's Disease Neuroimaging Initiative (ADNI) to explore the psychometric properties of the Clinical Dementia Rating Sum of Boxes (CDR-SB) to consider its utility as an outcome measure for clinical trials in early and mild, as well as later, stages of Alzheimer's disease (AD).
We assessed internal consistency, structural validity, convergent validity, and 2-year internal and external responsiveness of the CDR-SB using data from 382 subjects with early or mild AD at entry into the ADNI study.
The CDR-SB assesses both cognitive and functional domains of AD disability. Mean scores declined nearly linearly; CDR-SB cognitive and functional subsums contributed equally to total scores at both very mild (early) and mild stages of the disease.
The CDR-SB has psychometric properties that make it attractive as a primary outcome measure that comprehensively assesses both cognitive and functional disability in AD patients. It may prove particularly useful for studies in early, predementia stages of AD.
我们使用阿尔茨海默病神经影像学倡议 (ADNI) 的数据库来探索临床痴呆评定量表总和盒 (CDR-SB) 的心理计量学特性，以考虑其作为临床试验在早期和轻度，以及后期阶段阿尔茨海默病 (AD) 的结局测量的效用。
我们使用 ADNI 研究中 382 名早期或轻度 AD 患者的入组数据评估 CDR-SB 的内部一致性、结构效度、收敛效度以及 2 年的内部和外部反应性。
CDR-SB 评估了 AD 残疾的认知和功能领域。平均得分呈近线性下降；在疾病的极轻度（早期）和轻度阶段，CDR-SB 的认知和功能子量表对总分的贡献相等。
CDR-SB 具有心理计量学特性，使其作为全面评估 AD 患者认知和功能障碍的主要结局测量具有吸引力。它可能在 AD 的早期、前驱期阶段的研究中特别有用。
